The industry speaks: assessing the state of oligonucleotide manufacturing in 2026

Oligonucleotide therapeutics  are at an inflection point. With a growing pipeline of approved medicines and many more in clinical development, the pressure to  scale manufacturing efficiently and sustainably  has never been greater.

This pressing challenge brought together 36 leading experts from industry and academia  for an invitation-only event exploring the field's most urgent priorities — captured across  six live polls over two days .

Read the full infographic below

Please enter your email to access content Read now